- Home
- WLDN vs SLNO Comparison
WLDN vs SLNO Comparison
Compare WLDN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLDN | SLNO |
|---|---|---|
| Founded | 1964 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WLDN | SLNO |
|---|---|---|
| Price | $82.80 | $39.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $123.25 | $108.00 |
| AVG Volume (30 Days) | 304.4K | ★ 1.2M |
| Earning Date | 06-05-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | 108.90 |
| EPS | ★ 3.49 | 0.39 |
| Revenue | ★ $273,352,000.00 | $1,450,788.00 |
| Revenue This Year | N/A | $155.44 |
| Revenue Next Year | $12.05 | $57.99 |
| P/E Ratio | ★ $23.64 | $98.67 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $36.43 | $32.63 |
| 52 Week High | $137.00 | $89.12 |
Technical Indicators
Market Signals| Indicator | WLDN | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 48.10 |
| Support Level | $79.55 | $38.17 |
| Resistance Level | $100.15 | $44.60 |
| Average True Range (ATR) | 5.88 | 2.28 |
| MACD | -3.51 | 0.20 |
| Stochastic Oscillator | 12.46 | 75.19 |
Price Performance
Historical ComparisonAbout WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.